AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Protagonist Therapeutics, Inc.
Video analysis: PTGX
All videosNo video analysis for this stock yet. Request one from our team.
News: PTGX
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $9,289,446.64 in Stock
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) CEO Dinesh Ph Patel sold 63,548 shares of the company's stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $146.18, for a total transaction of $9,289,446.64. Following the completion of the sale, the chief executive officer directly owned 522,968
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $7,902,361.38 in Stock
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) CEO Dinesh Ph Patel sold 54,174 shares of the company's stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $145.87, for a total transaction of $7,902,361.38. Following the completion of the sale, the chief executive officer directly
Hsbc Holdings PLC Purchases 24,045 Shares of Protagonist Therapeutics, Inc. $PTGX
Hsbc Holdings PLC raised its position in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 1,260.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,952 shares of the company's stock after purchasing an additional 24,045 shares during the quarter. Hsbc Holdings PLC's holdings
Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
NEWARK, CA / ACCESS Newswire / September 8, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million of its outstanding common stock. The Company intends to fund the share repurchases from its cash, cash equivalents, and marketable securities, and from royalties and other payments received under the Company's collaboration arrangements with Takeda related to MIMRYLOTM (rusfertide) and with Johnson & Johnson related to ICOTYDETM (icotrokinra).
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
NEWARK, CA / ACCESS Newswire / September 2, 2026 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript
Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment
Protagonist Therapeutics NASDAQ: PTGX said the U.S. Food and Drug Administration has approved rusfertide, to be marketed as MIMRYLO, for the treatment of erythrocytosis in adults with polycythemia vera, or PV.
